NCT02609269

Decipher Genomics Resource for Intelligent Discovery

Prospective Expression Analysis Using The Decipher Genomics Resource for Intelligent Discovery (GRID)® and Data Sharing Program

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 1,000,000 (estimated)
• Sponsor: GenomeDx Biosciences Corp · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

To prospectively evaluate the utility of genomic expression data as a tool to better characterize the tumors of individual patients, and to understand how genomic information from individual patients undergoing routine clinical testing can be used in population-level analysis to improve treatment and outcomes.

Detailed description

Observational study involving the release of tumor genome-wide expression data generated by the Decipher assay which will be linked to clinical treatment and outcome data for patients in whom Decipher clinical testing was performed. The GRID database population will be used to characterize the genomics of cancer and discover or validate gene expression signatures that may be useful for understanding of the biology of the disease and implementing precision medicine approaches for cancer patients.

Conditions

• Prostate Cancer
• Bladder Cancer
• Renal Cancer

Interventions

Type	Name	Description
OTHER	Decipher Cancer Classifier	The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA \& CAP certified laboratory in San Diego, CA

Timeline

• Start date: 2015-10-01
• Primary completion: 2030-12-01
• Completion: 2040-12-01
• First posted: 2015-11-20
• Last updated: 2023-02-17